Commercial Development: In August 2025, Jocasta Neuroscience raised $35 million in Series A funding to advance JN-0413, a proprietary -klotho formulation, through Phase 1 trials with IND submission planned for Q4 2026
Individuals with specific genetic predispositions may experience greater improvements in stress resilience and cortisol regulation on semaglutide or tirzepatide, making genetic profiling valuable for treatment optimization
Establish a regular bathroom routine When it comes to bowel movements, it pays to become a creature of habit
Cho S, Huh H, Park S, et al
The difference was significant and immediate
During workouts, your body needs more fatty acids for fuel, and L-carnitine helps move stored fat into cells for energy